SAN

99.62

-0.56%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

PHIA

22.02

-3.97%↓

SAN

99.62

-0.56%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

PHIA

22.02

-3.97%↓

SAN

99.62

-0.56%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

PHIA

22.02

-3.97%↓

SAN

99.62

-0.56%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

PHIA

22.02

-3.97%↓

SAN

99.62

-0.56%↓

SHL.DE

46.38

-7.09%↓

ARGX

535.8

+0.3%↑

FRE

39.76

+0.86%↑

PHIA

22.02

-3.97%↓

Search

EssilorLuxottica SA

Slēgts

SektorsVeselības aprūpe

248.8 -7.03

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

244.1

Max

267.6

Galvenie mērījumi

By Trading Economics

Ienākumi

-371M

994M

Pārdošana

-72M

13B

P/E

Sektora vidējais

51.836

63.778

EPS

2.976

Dividenžu ienesīgums

1.48

Peļņas marža

7.52

Darbinieki

153,498

EBITDA

635M

3.6B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+7.78% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

1.48%

2.39%

Nākamie ieņēmumi

2025. g. 17. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

1.2B

122B

Iepriekšējā atvēršanas cena

255.83

Iepriekšējā slēgšanas cena

248.8

Ziņu noskaņojums

By Acuity

13%

87%

20 / 386 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

EssilorLuxottica SA Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 12. febr. 18:35 UTC

Peļņas

Ray-Ban Maker EssilorLuxottica Logs Higher Sales Amid North America, China Growth -- Update

2025. g. 12. febr. 17:32 UTC

Peļņas

Ray-Ban Maker EssilorLuxottica Posts Higher Profit on Sales Growth

2025. g. 2. janv. 17:29 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottica Buys AI Startup in Hearing Market Push

2025. g. 28. marts 08:57 UTC

Tirgus saruna

EssilorLuxottica Should Be Able to Cope With U.S. Volatility -- Market Talk

2025. g. 13. febr. 11:05 UTC

Tirgus saruna
Peļņas

EssilorLuxottica Seems Poised to Ride the Technology Wave -- Market Talk

2025. g. 13. febr. 10:54 UTC

Tirgus saruna
Peļņas

EssilorLuxottica's Midterm Margin Target Seems Challenging -- Market Talk

2025. g. 13. febr. 08:41 UTC

Tirgus saruna
Peļņas

EssilorLuxottica's Sales Are Better Than Expected -- Market Talk

2025. g. 12. febr. 17:05 UTC

Peļņas

EssilorLuxottica Backs Mid-Term Targets

2025. g. 12. febr. 17:05 UTC

Peļņas

EssilorLuxottica 2024 Oper Pft EUR3.45B

2025. g. 12. febr. 17:04 UTC

Peļņas

Analysts Had Seen EssilorLuxottica 2024 Net Pft at EUR2.50B

2025. g. 12. febr. 17:04 UTC

Peļņas

EssilorLuxottica 2024 Net Pft EUR2.36B

2025. g. 12. febr. 17:03 UTC

Peļņas

EssilorLuxottica 2024 Rev EUR26.51B

2025. g. 12. febr. 17:03 UTC

Peļņas

EssilorLuxottica 4Q Rev EUR6.78B

2025. g. 12. febr. 17:01 UTC

Peļņas

Analysts Had Seen EssilorLuxottica 4Q Rev at EUR6.68B

2025. g. 12. febr. 17:00 UTC

Peļņas

EssilorLuxottica Declares Dividend of EUR3.95 a share

2025. g. 11. febr. 16:30 UTC

Tirgus saruna

EssilorLuxottica Has Bright Future Ahead Amid Smart Glasses Push -- Market Talk

2025. g. 11. febr. 10:58 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

EssilorLuxottica Continues Ophthalmology Expansion With Cellview Acquisition -- Market Talk

2025. g. 11. febr. 07:03 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottica Doesn't Disclose Financial Details

2025. g. 11. febr. 07:03 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottica Aims to Build Wider Portfolio of Ophthalmic Instruments, Services With Deal

2025. g. 11. febr. 07:02 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottica: Toronto-Based Cellview Specializes in Diagnostic via Retinal Imaging

2025. g. 11. febr. 07:01 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottic Acquires Canadian Med-Tech Startup Cellview

2025. g. 11. febr. 07:00 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottica to Buy Cellview

2025. g. 2. janv. 17:04 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottica Didn't Disclose Financial Details

2025. g. 2. janv. 17:03 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottica: This Allows People With Hearing Impairment to Better Understand Speech

2025. g. 2. janv. 17:02 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottica: Pulse Audition Delivers AI-based Noise Reduction, Voice Enhancement

2025. g. 2. janv. 17:01 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottica Acquires Pulse Audition

2025. g. 2. janv. 17:00 UTC

Iegādes, apvienošanās, pārņemšana

EssilorLuxottica Strengthens Its Presence in Hearing Space With Acquisition of AI-driven Tech Startup in France

2024. g. 3. dec. 16:21 UTC

Tirgus saruna

EssilorLuxottica Could Be Hit by U.S. Tariffs -- Market Talk

2024. g. 6. nov. 09:01 UTC

Tirgus saruna

European Luxury Stocks Get Boost From Trump Potential Win -- Market Talk

2024. g. 18. okt. 07:08 UTC

Tirgus saruna
Peļņas

EssilorLuxottica Tries Soothe Nerves After Revenue Misses Forecasts -- Market Talk

Salīdzinājums

Cenas izmaiņa

EssilorLuxottica SA Prognoze

Cenas mērķis

By TipRanks

7.78% augšup

Prognoze 12 mēnešiem

Vidējais 288.2 EUR  7.78%

Augstākais 335 EUR

Zemākais 245 EUR

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi EssilorLuxottica SA — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

7

Pirkt

4

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

266.2 / 267.9Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

No Evidence

Noskaņojums

By Acuity

20 / 386 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par EssilorLuxottica SA

EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Essilor, Varilux, Crizal, Eyezen, Stellest, Xperio, Transitions, Ray-Ban, Oakley, Barberini, KODAK Lens, Nikon, Shamir, eyexpert, iWear, Humanware, and Optifog brands. It also provides finishing equipment, vision performance screening, eye examination and refractions, fitting parameter measurements, and small tools and consumables under the Essilor Instruments brand; high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the Satisloh brand. In addition, the company provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Vogue Eyewear, Arnette, Alain Mikli, Costa, Bliz, Native, Luxottica, Sferoflex, Bolon, Molsion, DbyD, and Unofficial and Seen, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of brick and mortar retail network and its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.